{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T09:21:30Z","timestamp":1772616090171,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Bayer-Schering AG"},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["337689"],"award-info":[{"award-number":["337689"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"German Ministry for Education and Research"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clim.2019.04.004","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T15:56:03Z","timestamp":1554738963000},"page":"45-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["MCC950 blocks enhanced interleukin-1\u03b2 production in patients with NLRP3 low penetrance variants"],"prefix":"10.1016","volume":"203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0721-8072","authenticated-orcid":false,"given":"E.","family":"Schuh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.J.","family":"Gro\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Schl\u00fcter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Gro\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"K\u00fcmpfel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2019.04.004_bb0005","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/bor.0000174210.78449.6b","article-title":"Familial autoinflammatory diseases: genetics, pathogenesis and treatment","volume":"17","author":"Stojanov","year":"2005","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.clim.2019.04.004_bb0010","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1067\/mai.2001.118790","article-title":"Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever","volume":"108","author":"Hoffman","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2019.04.004_bb0015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2133.1979.tb03572.x","article-title":"The 'Muckle-Wells' syndrome","volume":"100","author":"Muckle","year":"1979","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.clim.2019.04.004_bb0020","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/archderm.141.2.248","article-title":"Neonatal-onset multisystem inflammatory disorder: the emerging role of pyrin genes in autoinflammatory diseases","volume":"141","author":"Kilcline","year":"2005","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.clim.2019.04.004_bb0025","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1002\/art.10688","article-title":"De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases","volume":"46","author":"Aksentijevich","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2019.04.004_bb0030","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/ng756","article-title":"Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome","volume":"29","author":"Hoffman","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.clim.2019.04.004_bb0035","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1086\/341357","article-title":"Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes","volume":"71","author":"Feldmann","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.clim.2019.04.004_bb0040","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1074-7613(04)00046-9","article-title":"NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder","volume":"20","author":"Agostini","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2019.04.004_bb0045","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1212\/WNL.0b013e3181d9ed69","article-title":"Neurologic manifestations of the cryopyrin-associated periodic syndrome","volume":"74","author":"Kitley","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2019.04.004_bb0050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13023-017-0589-1","article-title":"Neurological outcome of patients with cryopyrin-associated periodic syndrome (CAPS)","volume":"12","author":"Mamoudjy","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.clim.2019.04.004_bb0055","first-page":"1","article-title":"Cryopyrin-associated periodic syndromes and autoinflammation","volume":"33","author":"Shinkai","year":"2008","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.clim.2019.04.004_bb0060","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1136\/annrheumdis-2013-204991","article-title":"Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry","volume":"74","author":"Levy","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2019.04.004_bb0065","first-page":"943","article-title":"Long-term clinical course of patients carrying the Q703K mutation in the NLRP3 gene: a case series","volume":"30","author":"Vitale","year":"2012","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.clim.2019.04.004_bb0070","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.3899\/jrheum.150962","article-title":"Clinical characteristics of patients carrying the Q703K variant of the NLRP3 gene: a 10-year Multicentric National Study","volume":"43","author":"Naselli","year":"2016","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2019.04.004_bb0075","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1212\/NXI.0000000000000109","article-title":"Expanding spectrum of neurologic manifestations in patients with NLRP3 low-penetrance mutations","volume":"2","author":"Schuh","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.clim.2019.04.004_bb0080","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1177\/0333102416629239","article-title":"Cryopyrin-associated periodic fever syndrome manifesting as Tolosa-Hunt syndrome","volume":"36","author":"Hohne","year":"2016","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clim.2019.04.004_bb0085","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/art.22491","article-title":"The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model","volume":"56","author":"Aksentijevich","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2019.04.004_bb0090","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/art.23286","article-title":"Gene polymorphisms in the NALP3 inflammasome are associated with interleukin-1 production and severe inflammation: relation to common inflammatory diseases?","volume":"58","author":"Verma","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2019.04.004_bb0095","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2019.04.004_bb0100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.it.2015.05.001","article-title":"The Nlrp3 inflammasome admits defeat","volume":"36","author":"Gross","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.clim.2019.04.004_bb0105","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.bbi.2016.12.014","article-title":"Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-beta and cognitive function in APP\/PS1 mice","volume":"61","author":"Dempsey","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.clim.2019.04.004_bb0110","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/STROKEAHA.117.018904","article-title":"Selective NLRP3 (Pyrin Domain-Containing Protein 3) Inflammasome Inhibitor Reduces Brain Injury After Intracerebral Hemorrhage","volume":"49","author":"Ren","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.clim.2019.04.004_bb0115","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1136\/annrheumdis-2016-209686","article-title":"Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS)","volume":"76","author":"Kuemmerle-Deschner","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2019.04.004_bb0120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.clim.2015.01.003","article-title":"A functional inflammasome activation assay differentiates patients with pathogenic NLRP3 mutations and symptomatic patients with low penetrance variants","volume":"157","author":"Rieber","year":"2015","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2019.04.004_bb0125","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1002\/art.40208","article-title":"Clinical and molecular phenotypes of low-penetrance variants of NLRP3: diagnostic and therapeutic challenges","volume":"69","author":"Kuemmerle-Deschner","year":"2017","journal-title":"Arthrit. Rheumatol."},{"key":"10.1016\/j.clim.2019.04.004_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034977","article-title":"The Q705K polymorphism in NLRP3 is a gain-of-function alteration leading to excessive interleukin-1beta and IL-18 production","volume":"7","author":"Verma","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2019.04.004_bb0135","doi-asserted-by":"crossref","first-page":"36617","DOI":"10.1074\/jbc.M112.407130","article-title":"Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation","volume":"287","author":"Juliana","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2019.04.004_bb0140","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","article-title":"The inflammasomes","volume":"140","author":"Schroder","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.clim.2019.04.004_bb0145","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.immuni.2013.08.037","article-title":"Mechanisms of NOD-like receptor-associated inflammasome activation","volume":"39","author":"Wen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2019.04.004_bb0150","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-065X.2011.01046.x","article-title":"The inflammasome: an integrated view","volume":"243","author":"Gross","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.clim.2019.04.004_bb0155","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.cell.2014.04.007","article-title":"Mechanisms and functions of inflammasomes","volume":"157","author":"Lamkanfi","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.clim.2019.04.004_bb0160","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/sj.cdd.4402195","article-title":"Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration","volume":"14","author":"Petrilli","year":"2007","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.clim.2019.04.004_bb0165","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.immuni.2013.05.016","article-title":"K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter","volume":"38","author":"Munoz-Planillo","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2019.04.004_bb0170","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.immuni.2016.08.010","article-title":"K+ efflux-independent NLRP3 inflammasome activation by small molecules targeting mitochondria","volume":"45","author":"Gross","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2019.04.004_bb0175","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2249.1990.tb08092.x","article-title":"The effect of gold sodium thiomalate and auranofin on lipopolysaccharide-induced interleukin-1 production by blood monocytes in vitro: variation in healthy subjects and patients with arthritis","volume":"79","author":"Danis","year":"1990","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2019.04.004_bb0180","doi-asserted-by":"crossref","first-page":"8473","DOI":"10.1016\/S0021-9258(18)68502-3","article-title":"The kinetics of interleukin 1 secretion from activated monocytes. Differences between interleukin 1 alpha and interleukin 1 beta","volume":"263","author":"Hazuda","year":"1988","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2019.04.004_bb0185","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/eji.1830190903","article-title":"Differences in the synthesis and kinetics of release of interleukin 1 alpha, interleukin 1 beta and tumor necrosis factor from human mononuclear cells","volume":"19","author":"Lonnemann","year":"1989","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2019.04.004_bb0190","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood.V91.2.577","article-title":"Lipopolysaccharide activates caspase-1 (interleukin-1-converting enzyme) in cultured monocytic and endothelial cells","volume":"91","author":"Schumann","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clim.2019.04.004_bb0195","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.immuni.2016.01.012","article-title":"Human monocytes engage an alternative inflammasome pathway","volume":"44","author":"Gaidt","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2019.04.004_bb0200","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1002\/art.22842","article-title":"Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations","volume":"56","author":"Gattorno","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2019.04.004_bb0205","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2172-7-29","article-title":"Standardization and performance evaluation of mononuclear cell cytokine secretion assays in a multicenter study","volume":"7","author":"Shreffler","year":"2006","journal-title":"BMC Immunol."},{"key":"10.1016\/j.clim.2019.04.004_bb0210","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1136\/annrheumdis-2012-201340","article-title":"Deficient production of IL-1 receptor antagonist and IL-6 coupled to oxidative stress in cryopyrin-associated periodic syndrome monocytes","volume":"71","author":"Carta","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2019.04.004_bb0215","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/cei.12361","article-title":"Impaired cytokine responses in patients with cryopyrin-associated periodic syndrome (CAPS)","volume":"177","author":"Haverkamp","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2019.04.004_bb0220","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.msard.2019.01.023","article-title":"Variants in NLRP3 and NLRC4 inflammasome associate with susceptibility and severity of multiple sclerosis","volume":"29","author":"Soares","year":"2019","journal-title":"Multiple Sclerosis Relat. Disord."},{"key":"10.1016\/j.clim.2019.04.004_bb0225","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/art.40055","volume":"69","author":"Rodriguez-Smith","year":"2017","journal-title":"Arthrit. Rheumatol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618307009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618307009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T13:29:25Z","timestamp":1663248565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661618307009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":45,"alternative-id":["S1521661618307009"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2019.04.004","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MCC950 blocks enhanced interleukin-1\u03b2 production in patients with NLRP3 low penetrance variants","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2019.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}